Purchase price of $5.25B; $2.2B stock consideration with remainder from new debt and cash on hand, committed to remain investment grade
Enhanced combined company growth and margin profile with expected $0.30 adj. EPS accretion in Year 1 and >$0.50 in Year 2
High single-digitadj. ROIC anticipated by Year 6
Expected to close by end of 2021
"We are thrilled to have the opportunity to bring our technologies and innovative cultures together to create seamless solutions to push science and discovery forward. We believe the joining of our teams poses a very exciting opportunity to accelerate discoveries in fast growing markets which will help life science researchers leverage ever developing technologies and novel approaches to better understand and fight disease."
Prahlad Singh
President and Chief
Executive Officer,
PerkinElmer Inc.
BioLegend: Global Innovator of Antibodies & Reagents
$380M Revenue
2022e
Revenue Split
55% North America
100% Recurring Revenue
25% Europe & ROW
Accretive Margin Profile
20% Asia Pacific
Global Reagents Center
10K
>700
Customers
of Excellence for
Legendary Discovery
Employees
130
Countries
Headquarters in San Diego, CA
Strategic Rationale
Further expands PKI in fast growing markets such as biologics, cell and gene therapy, proteogenomics, and recombinant proteins and increases PKI's overall mix of recurring and higher margin revenue
BioLegend's San Diego HQ to become content development engine for life science reagents and accelerate NPIs in high-growth opportunities
Will increase clinical impact by leveraging PKI's position in diagnostics and broad commercial reach
Further accelerates financial profile of combined company by adding 100 bps of organic growth and 300 bps of higher operating margin
Leading Global Player in Antibody &
Research Reagents
PKI and BioLegend:
Combined Research Portfolio
~$700M
2022e Revenue
+LDD Projected Growth
Attachments
Original document
Permalink
Disclaimer
PerkinElmer Inc. published this content on 26 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2021 10:57:03 UTC.
Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows:
- medical diagnosis equipment (61%);
- analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc.
Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).
REVVITY, INC. 
